Extracellular
adenosine is a potent immunosuppressor that accumulates during
tumor growth. We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of
monoclonal antibody (mAb)-based
therapy against CD73, an ecto-
enzyme overexpressed on
breast-cancer cells that catalyzes the dephosphorylation of
adenosine monophosphates into
adenosine. We showed that anti-CD73 mAb
therapy significantly delayed primary 4T1.2 and E0771
tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung
metastases. Notably, anti-CD73 mAb
therapy was essentially dependent on the induction of adaptive anti-
tumor immune responses. Knockdown of CD73 in 4T1.2
tumor cells confirmed the
tumor-promoting effects of CD73. In addition to its immunosuppressive effect, CD73 enhanced
tumor-cell chemotaxis, suggesting a role for CD73-derived
adenosine in
tumor metastasis. Accordingly, administration of adenosine-5'-N-ethylcarboxamide to
tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung
metastasis. Using selective
adenosine-receptor antagonists, we showed that activation of A2B
adenosine receptors promoted 4T1.2
tumor-cell chemotaxis in vitro and
metastasis in vivo. In conclusion, our study identified
tumor-derived CD73 as a mechanism of tumor immune escape and
tumor metastasis, and it also established the proof of concept that targeted
therapy against CD73 can trigger adaptive anti-
tumor immunity and inhibit
metastasis of
breast cancer.